Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FRNMBullishM&Anews

High materiality9/10

Freenome completes merger, secures $310M funding, to begin trading under FRNM

Jul 20, 2026, 4:05 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Significant near-term catalysts: Nasdaq listing, ~$310M capital raise, and high-profile partnerships; potential re-rating as visibility improves on revenue potential and clinical validation trajectory. Risks include execution delays, regulatory timelines, and market adoption of new screening tests.

AI summary

What happened, with direct paths to the underlying reporting

Freenome closed its merger with PCSC and will list on Nasdaq as FRNM on July 21, 2026. The deal yields roughly $310 million in gross proceeds, comprised of a $240 million PIPE and about $70 million from the PCSC trust, to fund its cancer-detection portfolio, AI-enabled multiomics platform, and commercialization with Abbott and Roche.

Freenome completes merger with PCSC; FRNM to trade Nasdaq July 21, 2026.
PIPE and trust deliver about $310 million gross proceeds.
Proceeds fund cancer-detection portfolio, AI multiomics, and Abbott/Roche commercialization.
Three pillars: portfolio expansion, clinical validation, and AI-driven platform.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Freenome completes merger, secures $310M funding, to begin trading under FRNM

FDA approval clears Freenome test as Abbott prepares U.S. launch